TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23829316

Group type: EXPERIMENTAL
Intervention: Narratives with no acknowledgment of personal responsibility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Narratives with moderate acknowledgment of personal responsibility
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (unrelated story)
Number of subjects: 0
Study: 21450579

Group type: EXPERIMENTAL
Intervention: Motivational counselling (MC) intervention group
Number of subjects: 141

Group type: COMPARATOR
Intervention: Usual care (UC) control group
Number of subjects: 141
Study: 20395684

Group type: EXPERIMENTAL
Intervention: Donepezil 5-10 mg/day
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 18315940

Group type: EXPERIMENTAL
Intervention: Intramuscular IFNbeta‐1a (Avonex) 30 microg once weekly
Number of subjects: 136

Group type: COMPARATOR
Intervention: Subcutaneous IFNbeta‐1a (Rebif) 44 microg three times per week
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: NAb+ patients
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: NAb- patients
Number of subjects: 136
Study: 15726299

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 662
Study: 14870956

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study: 10325723

Group type: EXPERIMENTAL
Intervention: Structured nurse-led discharge package (20 minute patient education programme and self management plan)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (standard discharge procedure)
Number of subjects: 160
Study: 7813335

Group type: EXPERIMENTAL
Intervention: Informed consent obtained 24 to 72 hours before the procedure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Informed consent obtained immediately before the procedure
Number of subjects: 60
Study: 1955129

Group type: EXPERIMENTAL
Intervention: Emergency esophageal variceal sclerotherapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Elective esophageal variceal sclerotherapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Emergency endoscopy alone
Number of subjects: 72
Study: 6759457

Group type: EXPERIMENTAL
Intervention: Bilopaque
Number of subjects: 45

Group type: COMPARATOR
Intervention: Telepaque
Number of subjects: 45
Study: 30944133

Group type: EXPERIMENTAL
Intervention: Chou-Ling-Dan (CLD) granules for 5 days
Number of subjects: 318

Group type: COMPARATOR
Intervention: Oseltamivir for 5 days
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 318
Study: 27870567

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Minimally Enhanced Usual Care
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Mindfulness skill of observing (MBCT)
Number of subjects: 189
Study: 27250730

Group type: EXPERIMENTAL
Intervention: Add-on breastfeeding-optimization program
Number of subjects: 784

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 784
Study: 24902492

Group type: EXPERIMENTAL
Intervention: South Asian patients with type 2 diabetes
Number of subjects: 1978

Group type: EXPERIMENTAL
Intervention: South Asian patients with type 2 diabetes (adjusted)
Number of subjects: 1978

Group type: COMPARATOR
Intervention: White European patients with type 2 diabetes
Number of subjects: 1978
Study: 22009665

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 90

Group type: COMPARATOR
Intervention: No video (Control)
Number of subjects: 90
Study: 19444734

Group type: EXPERIMENTAL
Intervention: Behavioral Naltrexone Therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Compliance Enhancement (Control)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intermittent cannabis use
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intensive behavioral therapy
Number of subjects: 63
Study: 17472953

Group type: EXPERIMENTAL
Intervention: Stork Test on the support side (2-point scale)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Stork Test on the support side (3-point scale)
Number of subjects: 33
Study: 14679382

Group type: EXPERIMENTAL
Intervention: Nutrition counselling for children and parents
Number of subjects: 98
Study: 14610711

Group type: EXPERIMENTAL
Intervention: Bolus tracking (group B)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Fixed delay (group F)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 10726104

Group type: EXPERIMENTAL
Intervention: 1.4 g/day of LC n‐3 PUFA
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 9

Group type: COMPARATOR
Intervention: MUFA/SFA content
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: LC n‐3 PUFA diet
Number of subjects: 9

Group type: COMPARATOR
Intervention: Meal MUFA/SFA study
Number of subjects: 9
Study: 8530611

Group type: EXPERIMENTAL
Intervention: Potassium bicarbonate (KHCO3, 2 meq/kg/day in divided doses)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (potassium chloride, 25 meq/day)
Number of subjects: 14
Study: 1837554

Group type: EXPERIMENTAL
Intervention: Laparoscopic GIFT (group 1)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Hysteroscopic GIFT (group 2)
Number of subjects: 131
Study: 6211981

Group type: COMPARATOR
Intervention: Ticarcillin plus amikacin (T + A)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Moxalactam plus amikacin (M + A)
Number of subjects: 191
Study: 31493863

Group type: EXPERIMENTAL
Intervention: Education and exercise (strengthening and neuromuscular control) targeting gluteal muscles
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Range of motion exercises
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Thermal modalities
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Electrotherapy
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Pain severity scales
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Single leg stance
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Global rating scores or standardised physical measures
Number of subjects: 361
Study: 29304417

Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG) measures during motor skill acquisition, consolidation, and interlimb transfer.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in PSI (phase slope index) between premotor, supplementary motor, and primary motor cortex (M1) electrodes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in PSI between M1 and parietal and primary sensory cortex (S1).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnitude of consolidated interlimb transfer correlated with PSI between bilateral M1s and between S1 and M1 in the non-practiced hemisphere.
Number of subjects: 0
Study: 27230903

Group type: EXPERIMENTAL
Intervention: Together at School intervention program
Number of subjects: 3704

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3704
Study: 25422026

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy combined with physical training
Number of subjects: 22
Study: 22495117

Group type: EXPERIMENTAL
Intervention: 1.9 µg HA + AS03B (5.93 mg α‐tocopherol) vaccine (6 mo‐9 y)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3.75 µg HA + AS03A (11.86 mg α‐tocopherol) vaccine (10‐17 y)
Number of subjects: 60
Study: 20090775

Group type: EXPERIMENTAL
Intervention: Pulse-pressure method (PPM)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Area method (AM)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Stroke volume/pulse‐pressure method (SVPP)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 320

Group type: COMPARATOR
Intervention: Correlation between methods
Number of subjects: 320

Group type: COMPARATOR
Intervention: Subgroup analysis for cardiovascular risk
Number of subjects: 320

Group type: COMPARATOR
Intervention: Echo parameters correlation
Number of subjects: 320
Study: 17642399

Group type: EXPERIMENTAL
Intervention: Xolair (omalizumab)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 15658946

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise and manipulative therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 200
Study: 11858330

Group type: EXPERIMENTAL
Intervention: Orthopaedic Research Institute-Ankle Strength Testing System (ORI-ASTS)
Number of subjects: 11
Study: 9794989

Group type: EXPERIMENTAL
Intervention: Standard formula containing docosahexaenoic acid (DHA)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 274

Group type: COMPARATOR
Intervention: Standard formula containing DHA and arachidonic acid
Number of subjects: 274

Group type: COMPARATOR
Intervention: Nonrandomized human milk comparison group
Number of subjects: 274
Study: 7906279

Group type: EXPERIMENTAL
Intervention: 1 mg SDZ CO 611
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 mg SDZ CO 611
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg/day SDZ CO 611
Number of subjects: 16
Study: 2669553

Group type: EXPERIMENTAL
Intervention: Topical glucocorticosteroids
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 236209

Group type: EXPERIMENTAL
Intervention: 0.1 N NaHCO3 (alkaline solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 30
Study: 31408377

Group type: EXPERIMENTAL
Intervention: Antidiabetic treatment with glyburide, metformin, or pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: MUO/T2D group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lean subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: MHO group
Number of subjects: 0
Study: 28323952

Group type: EXPERIMENTAL
Intervention: MUFA diet (olive oil)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fiber-rich diet
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (standard US food)
Number of subjects: 43
Study: 25487313

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 27

Group type: COMPARATOR
Intervention: OSAS patients before CPAP treatment
Number of subjects: 27
Study: 24056618

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction followed by tacrolimus monotherapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Basiliximab induction followed by tacrolimus and MMF maintenance
Number of subjects: 116
Study: 21401538

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg + Ondansetron 4 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 130
Study: 19921359

Group type: EXPERIMENTAL
Intervention: Group B+Mor+Mg (20 ml 0.25% bupivacaine, morphine 2 mg, magnesium 150 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group B+Mor (20 ml 0.25% bupivacaine, morphine 2 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group B+Mg (20 ml 0.25% bupivacaine, magnesium 150 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group B (20 ml 0.25% bupivacaine)
Number of subjects: 80
Study: 16636839

Group type: EXPERIMENTAL
Intervention: Digital color, red‐free and red light imaging
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Subtraction method
Number of subjects: 110

Group type: COMPARATOR
Intervention: Digital imaging
Number of subjects: 110
Study: 14558954

Group type: EXPERIMENTAL
Intervention: Ulinastatin 5,000 u/kg preoperatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no ulinastatin)
Number of subjects: 60
Study: 10992996

Group type: EXPERIMENTAL
Intervention: Pharmacological lipid therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle changes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard lipid therapy in secondary prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary prevention lipid therapy
Number of subjects: 0
Study: 9347245

Group type: EXPERIMENTAL
Intervention: Troglitazone (TR), 200 mg once daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 23
Study: 8185689

Group type: EXPERIMENTAL
Intervention: Minocycline (maximal oral daily dose 200 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 80
Study: 2885450

Group type: EXPERIMENTAL
Intervention: Isovolaemic haemodilution
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham dilutions (Control)
Number of subjects: 24
Study: 29377462

Group type: EXPERIMENTAL
Intervention: selonsertib (SEL) 6 mg or 18 mg orally QD
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Baseline serum CK-18, IL-6 and CRP
Number of subjects: 72
Study: 28826616

Group type: EXPERIMENTAL
Intervention: Lenalidomide (10 mg/day for 3 months, then escalated to 15 mg/day)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 460
Study: 27111772

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 23517884

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study: 21585060

Group type: EXPERIMENTAL
Intervention: Acupoint-catgut-embedment (ACE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medication (Rupixiao)
Number of subjects: 80
Study: 19364999

Group type: EXPERIMENTAL
Intervention: Physical activity advice and prescription by physicians (intervention group)
Number of subjects: 4317

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 4317
Study: 16937497

Group type: EXPERIMENTAL
Intervention: Empirical endoscopy
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: H pylori test-and-treat
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Empirical prokinetic treatment with cisapride
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 234
Study: 15291205

Group type: EXPERIMENTAL
Intervention: Expression of negative emotions (writing about unpleasant experiences)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Inhibition of negative emotions (suppressing emotional responses)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Expression of emotions
Number of subjects: 32
Study: 11368137

Group type: EXPERIMENTAL
Intervention: Carrier screening for fragile X syndrome, aspartylglycosaminuria, and infantile neuronal ceroid lipofuscinosis
Number of subjects: 256
Study: 9272316

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ophthalmic solution (0.3%)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Tobramycin ophthalmic solution
Number of subjects: 257
Study: 8221366

Group type: EXPERIMENTAL
Intervention: Oculokinetic perimetry (OKP) screener
Number of subjects: 75

Group type: COMPARATOR
Intervention: Friedmann field analyser standard program
Number of subjects: 75

Group type: COMPARATOR
Intervention: Humphrey field analyser 40-point screening program
Number of subjects: 75
Study: 2891333

Group type: EXPERIMENTAL
Intervention: Pyrazinamide-containing regimens (Regimens 1 to 4 combined)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Nonpyrazinamide series (Regimen 5)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Pyrazinamide series
Number of subjects: 833

Group type: COMPARATOR
Intervention: Nonpyrazinamide series
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Pyrazinamide series (for patients with strains resistant to isoniazid, streptomycin, or both)
Number of subjects: 833
Study: 28923985

Group type: EXPERIMENTAL
Intervention: Clamping after at least 2 minutes and immediate neonatal care with cord intact
Number of subjects: 261

Group type: COMPARATOR
Intervention: Clamping within 20 seconds and immediate neonatal care after clamping
Number of subjects: 261
Study: 28002709

Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate for 5 days
Number of subjects: 520

Group type: COMPARATOR
Intervention: Amoxicillin‐clavulanate for 10 days
Number of subjects: 520
Study: 24078373

Group type: EXPERIMENTAL
Intervention: Family skills training intervention (SFP 10-14) in 10 schools with 371 students
Number of subjects: 587

Group type: COMPARATOR
Intervention: Control group in 9 schools with 216 students
Number of subjects: 587
Study: 22222208

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Intolerance-of-uncertainty therapy (IUT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Delayed treatment (DT)
Number of subjects: 126
Study: 20363092

Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus varenicline
Number of subjects: 542
Study: 18691579

Group type: COMPARATOR
Intervention: Endoluminal image analysis using capsule technology (Pillcam)
Number of subjects: 86
Study: 15820911

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 49

Group type: COMPARATOR
Intervention: Comparison of real and placebo acupuncture
Number of subjects: 49
Study: 12671113

Group type: EXPERIMENTAL
Intervention: GlucoWatch biographer
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 40
Study: 11029132

Group type: EXPERIMENTAL
Intervention: Alcohol gel hand sanitizer used by students and staff when entering and leaving the classroom.
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Control group (no alcohol gel hand sanitizer used).
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Alcohol gel hand sanitizer used in schools with the largest teacher population (n = 246).
Number of subjects: 6000
Study: 8640699

Group type: EXPERIMENTAL
Intervention: Fadrozole HCL, 1 mg twice daily
Number of subjects: 683

Group type: COMPARATOR
Intervention: Megestrol acetate, 40 mg 4 times daily
Number of subjects: 683
Study: 7690082

Group type: EXPERIMENTAL
Intervention: Clonidine 0.5 micrograms/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Clonidine 1 micrograms/kg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3535990

Group type: EXPERIMENTAL
Intervention: One year's adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5‐fluorouracil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by chemotherapy
Number of subjects: 0
Study: 29670330

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (120 mg/day)
Number of subjects: 60
Study: 27128642

Group type: EXPERIMENTAL
Intervention: Resource Mothers Program (RMP) home visiting
Number of subjects: 150

Group type: COMPARATOR
Intervention: Telephone support control group
Number of subjects: 150
Study: 25037843

Group type: EXPERIMENTAL
Intervention: Outreach model (individualized in-home strategy; n = 125)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Center model (community center largely with groups; n = 121)
Number of subjects: 246
Study: 23053830

Group type: EXPERIMENTAL
Intervention: Co-located behavioral health services in primary care practices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced referral procedure for external locations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referral as usual to regional children's hospital
Number of subjects: 0
Study: 20347544

Group type: EXPERIMENTAL
Intervention: Routine Shunting (RS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Selective Shunting (SS)
Number of subjects: 200
Study: 18512141

Group type: EXPERIMENTAL
Intervention: Educational workshops (n = 52)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control video session (n = 55)
Number of subjects: 107
Study: 15936729

Group type: EXPERIMENTAL
Intervention: 1-hertz left temporoparietal repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 50
Study: 12817758

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily for 3 years
Number of subjects: 693

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 693
Study: 10100116

Group type: EXPERIMENTAL
Intervention: Sagittal plane hold-relax exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Static stretch
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 8866927

Group type: EXPERIMENTAL
Intervention: CFC-free metered-dose inhaler (CFC-free)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CFC metered-dose inhaler (CFC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dry powder inhaler (DPI)
Number of subjects: 12
Study: 1801963

Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate (50 mg, tablet) after overnight fast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fluvoxamine maleate (50 mg, tablet) after breakfast
Number of subjects: 12
Study: 6144244

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Relaxation Therapy (R)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Supportive Therapy of Dynamic Type (ST)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Basal Therapy (B)
Number of subjects: 103
Study: 31624633

Group type: EXPERIMENTAL
Intervention: PF-04895162
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DILIsym modeling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated human hepatotoxicity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher PF-04895162 liver exposures
Number of subjects: 0
Study: 29956827

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Number of subjects: 647
Study: 26762838

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anti-TNF agents (anti-TNF group)
Number of subjects: 100